Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as Biocytogen) is an international biotechnology company that uses innovative technologies to drive the research and development of novel therapeutics to improve human health around the world. Centered around the fully human antibody mice, RenMabTM, RenLite TM models, which are independently developed and completely independent with intellectual property rights, Biocytogen has integrated its platforms in single-cell antibody discovery, efficient genetically modified animal model development, large-scale animal model supply, rapid animal efficacy evaluation in vivo and in vitro, and powerful clinical development capability, to forma comprehensive drug development program that spans the entire drug development process.
Biocytogen actively promotes the independent and cooperative development of new drugs. With the implementation of the “RenMice HiTS Platform” for large-scale antibody drug development, the company will focus more on internal drug development. In the future, the company will also join hands with global partners to accelerate the process of new drug development. Biocytogen is headquartered in Beijing, with branches in Haimen, Jiangsu, Boston, Shanghai. Its wholly-owned subsidiary, Eucure Biopharma, focuses on clinical development.